1030377-33-3|Suvorexant|MK-4305|-范德生物科技公司

Suvorexant

NMR下载 COA and HPLC MSDS下载
names：
MK-4305
CAS号：
1030377-33-3
MDL Number：
MF(分子式)： C23H23ClN6O2 MW(分子量)： 450.921
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

Suvorexant(1030377-33-3)also known as MK-4305, is a discontinued (DEA controlled substance) biochemical.

货品编码	规格	纯度	价格 (¥)	现价(¥)	库存描述	数量	总计 (¥)
HCC345829-1g	1g	99.2%	¥ 0.00	¥ 0.00	Instock	- +	¥ 0.00
HCC345829-100mg	100mg	99.2%	¥ 5250.00	¥ 5250.00	Instock	- +	¥ 0.00
HCC345829-20mg	20mg	99.2%	¥ 3250.00	¥ 3250.00	Instock	- +	¥ 0.00
HCC345829-5mg	5mg	99.2%	¥ 1130.00	¥ 1130.00	Instock	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Suvorexant;(1030377-33-3)
英文别名	Suvorexant,MK-4305,MK4305,MK 4305,1030377-33-3;
CAS号	1030377-33-3
SMILES	Cc1ccc(c(c1)C(=O)N2CCN(CC[C@H]2C)c3nc4cc(ccc4o3)Cl)n5nccn5
Inchi	InChI=1S/C23H23ClN6O2/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3/t16-/m1/s1
InchiKey	JYTNQNCOQXFQPK-MRXNPFEDSA-N
分子式 Formula	C23H23ClN6O2
分子量 Molecular Weight	450.921
闪点 FP	358.9±34.3 °C
熔点 Melting point	131-133°C
沸点 Boiling point	669.8±65.0 °C at 760 mmHg
Polarizability极化度	48.9±0.5 10-24cm3
密度 Density	1.4±0.1 g/cm3
蒸汽压 Vapor Pressure	0.0±2.0 mmHg at 25°C
溶解度Solubility	Chloroform (Slightly), DMSO (Slightly, Heated), Methanol (Slightly, Heated)
性状	solid power
储藏条件 Storage conditions	Room Temperature

Suvorexant(1030377-33-3)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

产品说明	Suvorexant;(1030377-33-3,MK-4305)可以作为药物杂质对照品以及生物医药类试剂。
Introduction	Suvorexant（1030377-33-3） can be used as a reference substance for drug impurities and reagents，only for research.
Application1
Application2
Application3

警示图
危险性	warning
危险性警示	Not available
安全声明	H303+H313+H333
安全防护	P264+P280+P305+P351+P338+P337+P313
备注	实验过程中防止吸入、食入，做好安全防护

Christopher John A., Aves Sarah J., Brown Jason, Errey James C., Klair Suki S., Langmead Christopher J., Mace Oliver J., Mould Richard, Patel Jayesh C., Tehan Benjamin G., Zhukov Andrei, Marshall Fiona H., Congreve Miles.Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties,Med. Chem. Commun., 2015[DOI: 10.1039C5MD00027K]

1: McGaughey G, Bayly CI, Cox CD, Schreier JD, Breslin MJ, Bogusky M, Pitzenberger S, Ball R, Coleman PJ. Shaping suvorexant: application of experimental and theoretical methods for driving synthetic designs. J Comput Aided Mol Des. 2014 Jan;28(1):5-12. doi: 10.1007/s10822-014-9710-x. Epub 2014 Feb 1. PubMed PMID: 24488306; PubMed Central PMCID: PMC3927067.

2: Hoyer D, DÃ¼rst T, Fendt M, Jacobson LH, Betschart C, Hintermann S, Behnke D, Cotesta S, Laue G, Ofner S, Legangneux E, Gee CE. Distinct effects of IPSU and suvorexant on mouse sleep architecture. Front Neurosci. 2013 Dec 10;7:235. doi: 10.3389/fnins.2013.00235. eCollection 2013. PubMed PMID: 24368893; PubMed Central PMCID: PMC3857892.

3: Sun H, Kennedy WP, Wilbraham D, Lewis N, Calder N, Li X, Ma J, Yee KL, Ermlich S, Mangin E, Lines C, Rosen L, Chodakewitz J, Murphy GM. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep. 2013 Feb 1;36(2):259-67. doi: 10.5665/sleep.2386. PubMed PMID: 23372274; PubMed Central PMCID: PMC3542986.

4: Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, Lines C, Roth T, Michelson D. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012 Dec 4;79(23):2265-74. doi: 10.1212/WNL.0b013e31827688ee. Epub 2012 Nov 28. PubMed PMID: 23197752.

5: Hopkins CR. ACS chemical neuroscience molecule spotlight on Suvorexant. ACS Chem Neurosci. 2012 Sep 19;3(9):647-8. Review. PubMed PMID: 23024835; PubMed Central PMCID: PMC3447389.

6: Strotman NA, Baxter CA, Brands KM, Cleator E, Krska SW, Reamer RA, Wallace DJ, Wright TJ. Reaction development and mechanistic study of a ruthenium catalyzed intramolecular asymmetric reductive amination en route to the dual Orexin inhibitor Suvorexant (MK-4305). J Am Chem Soc. 2011 Jun 1;133(21):8362-71. doi: 10.1021/ja202358f. Epub 2011 May 11. PubMed PMID: 21528938.

7: Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, Breslin MJ, Garson SL, Fox SV, Harrell CM, Stevens J, Reiss DR, Cui D, Coleman PJ, Renger JJ. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J Neurogenet. 2011 Mar;25(1-2):52-61. doi: 10.3109/01677063.2011.566953. Epub 2011 Apr 8. PubMed PMID: 21473737.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开